These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31657130)

  • 1. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
    Machauer R; Lueoend R; Hurth K; Veenstra SJ; Rueeger H; Voegtle M; Tintelnot-Blomley M; Rondeau JM; Jacobson LH; Laue G; Beltz K; Neumann U
    J Med Chem; 2021 Oct; 64(20):15262-15279. PubMed ID: 34648711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360.
    Rueeger H; Lueoend R; Machauer R; Veenstra SJ; Holzer P; Hurth K; Voegtle M; Frederiksen M; Rondeau JM; Tintelnot-Blomley M; Jacobson LH; Staufenbiel M; Laue G; Neumann U
    J Med Chem; 2021 Apr; 64(8):4677-4696. PubMed ID: 33844524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
    Rombouts FJ; Tresadern G; Delgado O; Martínez-Lamenca C; Van Gool M; García-Molina A; Alonso de Diego SA; Oehlrich D; Prokopcova H; Alonso JM; Austin N; Borghys H; Van Brandt S; Surkyn M; De Cleyn M; Vos A; Alexander R; Macdonald G; Moechars D; Gijsen H; Trabanco AA
    J Med Chem; 2015 Oct; 58(20):8216-35. PubMed ID: 26378740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
    Gijsen HJM; Alonso de Diego SA; De Cleyn M; García-Molina A; Macdonald GJ; Martínez-Lamenca C; Oehlrich D; Prokopcova H; Rombouts FJR; Surkyn M; Trabanco AA; Van Brandt S; Van den Bossche D; Van Gool M; Austin N; Borghys H; Dhuyvetter D; Moechars D
    J Med Chem; 2018 Jun; 61(12):5292-5303. PubMed ID: 29809004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
    Wu YJ; Guernon J; Shi J; Marcin L; Higgins M; Rajamani R; Muckelbauer J; Lewis H; Chang C; Camac D; Toyn JH; Ahlijanian MK; Albright CF; Macor JE; Thompson LA
    J Med Chem; 2016 Sep; 59(18):8593-600. PubMed ID: 27559936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction.
    Nakahara K; Mitsuoka Y; Kasuya S; Yamamoto T; Yamamoto S; Ito H; Kido Y; Kusakabe KI
    Eur J Med Chem; 2021 Apr; 216():113270. PubMed ID: 33765486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.
    Nakahara K; Fuchino K; Komano K; Asada N; Tadano G; Hasegawa T; Yamamoto T; Sako Y; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jul; 61(13):5525-5546. PubMed ID: 29775538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
    Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
    J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.
    Filser S; Ovsepian SV; Masana M; Blazquez-Llorca L; Brandt Elvang A; Volbracht C; Müller MB; Jung CK; Herms J
    Biol Psychiatry; 2015 Apr; 77(8):729-39. PubMed ID: 25599931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
    Koriyama Y; Hori A; Ito H; Yonezawa S; Baba Y; Tanimoto N; Ueno T; Yamamoto S; Yamamoto T; Asada N; Morimoto K; Einaru S; Sakai K; Kanazu T; Matsuda A; Yamaguchi Y; Oguma T; Timmers M; Tritsmans L; Kusakabe KI; Kato A; Sakaguchi G
    J Med Chem; 2021 Feb; 64(4):1873-1888. PubMed ID: 33588527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.
    Shimshek DR; Jacobson LH; Kolly C; Zamurovic N; Balavenkatraman KK; Morawiec L; Kreutzer R; Schelle J; Jucker M; Bertschi B; Theil D; Heier A; Bigot K; Beltz K; Machauer R; Brzak I; Perrot L; Neumann U
    Sci Rep; 2016 Feb; 6():21917. PubMed ID: 26912421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.